It has been reported that metformin can synergize with gefitinib, inhibiting cell growth, and reducing AKT/PI3K/mTOR pathway activity in LKB1 wild-type NSCLC cell lines [119]. Here, AKT1 is linked to non-small cell lung carcinoma.